<DOC>
	<DOC>NCT02583828</DOC>
	<brief_summary>This is a randomized clinical trial to investigate the efficacy of letrozole combined with metronomic oral cyclophosphamide in elderly metastasis breast cancer patients.</brief_summary>
	<brief_title>Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Histologically confirmed metastatic breast cancers patients with estrogen receptor positive and/or progesterone receptor positive; Elderly women (age â‰¥ 65years) Failure or relapse from standard chemotherapy or unfit for chemotherapy Measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST); Eastern Cooperative Oncology Group (ECOG) performance status of 02; Adequate bone marrow, liver and renal function; Estimated life expectancy of at least 3 months. Serious or uncontrolled concurrent medical illness Uncontrolled primary and metastatic brain tumor History of second primary malignancies Having been enrolled in other clinical trials within a month</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>